Leqembi’s EU Approval Process Delayed Over Advisory Group COI Considerations
The decision is not related to the product.
The EU regulatory agency’s discussions for lecanemab’s approval are hit by a decision to annul advice from an advisory committee due to the implications of a Court of Justice ruling on the handling of experts' competing interests.
